精囊凝胶蛋白1在膀胱肿瘤组织中的表达及意义

发布时间：2018-03-11 20:10

本文选题：精囊凝胶蛋白1　切入点：膀胱癌　出处：《南京医科大学》2014年硕士论文　论文类型：学位论文

【摘要】：2008年,美国有68810名新的膀胱肿瘤患者出现,同时有14100名患者死于膀胱肿瘤。对于非侵袭性的膀胱肿瘤而言,其有很高的复发概率；而对于侵袭性的膀胱肿瘤,患者术后的5年生存率很差,这些现状使得膀胱肿瘤患者的治疗和预后面临一个很大的挑战。目前,经尿道膀胱电切术和根治性膀胱全切术分别是治疗非侵袭性和侵袭性膀胱肿瘤最好的方法。然而对于侵袭性的膀胱肿瘤患者,根治性膀胱全切术后的长期生存率很低。与预后差有关的因素包括淋巴结转移,肿瘤细胞分化差以及肿瘤分级较高等。然而,到目前为止,可以用来预测膀胱肿瘤预后的生物标记物还是很有限的,所以一个新的与膀胱肿瘤预后相关的生物标记物是迫切需要的。精囊凝胶蛋白1主要由精囊上皮合成并分泌,是男性射精后精液凝固物的主要结构蛋白。精囊凝胶蛋白1在精液中的作用机制研究的比较彻底,其主要的功能是抑制射精后精子的活动以及参与其后的精液液化过程。精囊凝胶蛋白1发现存在与其他非生殖系统的组织器官之中,比如正常的组织：气管,腮腺,胰腺等,同时也存在与一些恶性肿瘤的组织中,如：肺癌组织,骨髓瘤组织和白血病。因此精囊凝胶蛋白1与肿瘤的关系受到了越来越多的关注,但是其与泌尿系统的肿瘤之间的关系却没有深入研究过,本文开创性的第一次研究了精囊凝胶蛋白1在膀胱癌组织的表达和关系。我们运用免疫组化的技术检测了46个膀胱癌组织中的精囊凝胶蛋白1的表达情况。同时运用western blotting和实时定量PCR技术分别从蛋白质和基因的水平检测了精囊凝胶蛋白1在15对膀胱癌组织以及其相对应的癌旁组织中的表达。Western blotting和实时定量PCR的结果证实精囊凝胶蛋白1在癌旁组织中的表达明显的高于像对应的肿瘤组织。免疫组化染色的结果进一步揭示精囊凝胶蛋白1的表达与肿瘤的分期,分级和转移相关,有统计学意义。Kaplan曲线和log-rank检验揭示了肿瘤组织中精囊凝胶蛋白1的表达较高的术后患者较表达较低的患者有一个更好的术后生存率,差异是有统计学意义的。综上所述,本研究第一次提出了精囊凝胶蛋白1可以作为一个膀胱癌的新的预后以及病理诊断的生物标记物。但是具体的生物分子学机制尚需要我们去做进一步的研究。
[Abstract]:In 2008, 68810 new bladder cancer patients appeared in the United States, while 14100 died of bladder cancer. The 5-year survival rate is poor, which poses a great challenge to the treatment and prognosis of bladder cancer patients. Transurethral cystectomy and radical cystectomy are the best treatments for noninvasive and invasive bladder neoplasms, respectively. The long-term survival rate after radical cystectomy is very low. Factors associated with poor prognosis include lymph node metastasis, poor differentiation of tumor cells, and higher tumor grade. The biomarkers that can be used to predict the prognosis of bladder tumors are still limited, so a new biomarker related to the prognosis of bladder tumors is urgently needed. Seminal vesicle gel protein 1, which is mainly synthesized and secreted by seminal vesicle epithelium, is the main structural protein of semen coagulant after ejaculation. Its main function is to inhibit sperm activity after ejaculation and to participate in the subsequent semen liquefaction. Seminal vesicle gel protein-1 is found to exist in tissues and organs of other non-reproductive systems, such as normal tissues: trachea, parotid gland, pancreas, etc. At the same time, there are also some malignant tumor tissues, such as lung cancer, myeloma and leukemia. Therefore, the relationship between seminal vesicle gel protein 1 and tumor has been paid more and more attention. However, the relationship between seminal vesicle gel protein-1 and urological tumors has not been studied in depth. This paper has studied the expression and relationship of seminal vesicle gel protein 1 in bladder cancer for the first time. The expression of seminal vesicle gel protein-1 in 46 bladder cancer tissues was detected by immunohistochemical technique. Meanwhile, western blotting and real-time quantitative PCR were used to detect seminal vesicle gel at the protein and gene levels, respectively. The expression of protein 1 in 15 pairs of bladder cancer tissues and its corresponding adjacent tissues. Western blotting and real-time quantitative PCR confirmed that the expression of seminal vesicle gel protein 1 in adjacent tissues was significantly higher than that in corresponding tumor tissues. The results of immunohistochemical staining further revealed the expression of seminal vesicle gel protein-1 and tumor staging. Grade and metastasis were correlated. Kaplan curve and log-rank test showed that the patients with higher expression of seminal vesicle gel protein-1 had a better postoperative survival rate than those with lower expression, and the difference was statistically significant. In conclusion, this study proposed for the first time that seminal vesicle gel protein-1 may be a new biomarker for the prognosis and pathological diagnosis of bladder cancer, but the specific biomolecular mechanism needs to be further studied.
【学位授予单位】：南京医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.14

【相似文献】